Assays for Fibrinogen-Fibrin Degradation Products in Biological Fluids: Some Methodological Aspects^[*]

 

^* Presented at the Postgraduate Course and Workshop “Progress in Fibrinolysis”. Milano, Italy, March 6–8, 1975.

• References

• 1 Allington M. J. 1971; Detection of fibrin(ogen) degradation products by a latex clumping method. Scandinavian Journal of Haematology Suppl. 13: 115.
• 2 Arnesen H, and Ly B. 1974; FR-antigens in serum after coagulation at low pH. Thrombosis Research 5: 93.
• 4 Arnesen H, Ly B, and Odegård O. R. 1973; Improved quantitation of serum FDP after coagulation at low pH. Thrombosis Research 3: 643.
• 5 Arocha-Piñango C. L. 1972; A comparison of the TRCII and latex-particle tests for the titration of FR-antigen. Journal of Clinical Pathology 25: 757.
• 6 Beller F. K, and Maki M. 1967; Properties of fibrinogenolysis and fibrinolysis products in immune assays. Thrombosis et Diathesis Haemorrhagica 18: 114.
• 7 Benz J. J. 1968; Clotting factors and fibrinogen split products in the extravascular space. Thrombosis et Diathesis Haemorrhagica 19: 226.
• 8 Budzynski A. Z, and Marder V. J. 1975; Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood. Thrombosis et Diathesis Haemorrhagica 34: 709.
• 9 Carvalho A. C. A, Ellman L. L, and Colman R. W. 1974; A comparison of the staphylococcal clumping test and an agglutination test for detection of fibrinogen degradation products. American Journal of Clinical Pathology 62: 107.
• 10 Catanzaro A, and Edgington T. S. 1974; The in vivo behavior of the terminal derivatives of fibrinogen and fibrin cleaved by plasmin. Journal of Laboratory and Clinical Medicine 83: 458.
• 11 Catt K. J, Hirsh J, Castelan D. J, Niall H. D, and Tregear G. W. 1968; Radioimmunoassay of fibrinogen and its proteolysis products. Thrombosis et Diathesis Haemorrhagica 20: 1.
• 12 Donati M. B, Casteels-Van Daele M, Hens G, Vermylen J, and Eeckels R. 1973; a Hypofibrinogenemia in histiocytosis X, type Letterer-Siwe disease. Helvetica Paediatrica Acta 28: 603.
• 13 Donati M. B, Molla A, Michielsen P, and Vermylen J. 1974; Measurement of urinary fibrinogen-related material: methodologie aspects. Journal of Laboratory and Clinical Medicine 83: 921.
• 14 Donati M. B, Molla A, and Vermylen J. 1971; b The tanned red cell hemagglutination inhibition immunoassay and purified fibrinogen degradation products. Scandinavian Journal of Haematology Suppl. 13: 91.
• 15 Donati M. B, Semeraeo N, and Vermylek J. 1973; b Detection of fibrinogen antigens with two latex techniques applied to urine concentrates. Journal of Clinical Pathology 26: 760.
• 16 Donati M. B, Vermylen J, Verstraete M. 1971; a The staphylococcal clumping test for detection of fibrinogen-like material. Scandinavian Journal of Haematology Suppl.13: 137.
• 17 Dudek G. A, Kłoczewiak M, Budzynski A. Z, Latałło Z. S, and Kopeć M. 1970; Characterisation and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin. Biochimica et Biophysica Acta 214: 44.
• 18 Finkelstein A. E, Alexander B, and Roisman F. 1974; New nonimmunological method of measuring fibrinogen-fibrin degradation products. Thrombosis Research 4: 567.
• 19 Gaffney P. J. 1973; Subunit relationships between fibrinogen and fibrin degradation products. Thrombosis Research 2: 201.
• 20 Gaffney P. J, and Brasher M. 1973; Methods of examining fibrinolysis in plasma. Nature 244: 361.
• 21 Gordon Y. B, Martin M. J, McNeile A. T, and Chard T. 1973; Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay. Lancet 2: 1168.
• 22 Hahn L. 1974; The tanned red cell hemagglutination-inhibition immunoassay of fibrinogen-fibrin degradation products. Methodological and statistical aspects. Thrombosis Research 4: 417.
• 23 Hawiger J, Niewiarowski S, Gurewich V, and Thomas D. P. 1970; Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. Journal of Laboratory and Clinical Medicine 75: 93.
• 24 Hedner U. 1975; Urinary fibrin/fibrinogen derivatives. Thrombosis et Diathesis Haemorrhagica 34: 693.
• 25 Hedner U, Ekberg M, and Nilsson I. M. 1974; Urinary fibrin/fibrinogen degradation products (FDP) and glomerulonephritis. Acta Medica Scandinavica 195: 81.
• 26 Hoq M.S, and Cash J. D. 1973; Studies on a direct latex agglutination-technique for the semiquantitation of fibrin/fibrinogen degradation products. Thrombosis Research 2: 23.
• 27 Kolodie L, Rachail M, and Seigneurin D. 1973; Dosage des produits de dégradation de la fibrine (FDP) dans le sérum au cours des cirrhoses du foie. Lyon Médical 229: 671.
• 28 Laurell C.-B. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 15: 45.
• 29 Leavelle D. E, Bowie E. J. W, Mertens B. F, McDuffle F. C, and Owen Jr. C. A. 1971; Assay for fibrinolytic split products: comparison of staphylococcal clumping and hemagglutination-inhibition tests. Journal of Laboratory and Clinical Medicine 77: 993.
• 30 Lewis J. H, and Wilson J. H. 1973; Variations in abilities of animal fibrinogens to clump staphylococci. Thrombosis Research 3: 419.
• 31 Lipinski B, Nowak A, Odrzywolska A, and Dosiak J. 1971; Relationship between plasma fibrinolytic activity and serum fibrinogen degradation products (FDP) tested by various methods. Thrombosis et Diathesis Haemorrhagica 26: 83.
• 32 Mancini G, Carbonara O, and Heremans J. F. 1965; Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235.
• 33 Marder V. J, Matchett M. O, and Sherry S. 1971; Detection of serum fibrinogen and fibrin degradation products. American Journal of Medicine 51: 71.
• 34 Marder V. J, Shulman N. R, and Carroll W. R. 1969; High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. Journal of Biological Chemistry 244: 2111.
• 35 Merskey C. 1973; Editorial: Defibrination syndrome or. ? Blood 41: 599.
• 36 Merskey C, Johnson A. J, Kleiner G. J, and Wohl H. 1967; The defibrination syndrome: clinical features and laboratory diagnosis. British Journal of Haematology 13: 528.
• 37 Merskey C, Johnson A. J, and Lalezari P. 1972; Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin. Journal of Clinical Investigation 51: 903.
• 38 Merskey C, Lalezari P, and Johnson A. J. 1969; A rapid, simple sensitive method for measuring fibrinolytic split products in human serum. Proceedings of the Society for Experimental Biology and Medicine 131: 871.
• 39 Molla A, Donati M. B, Dotremont G, and Vermylen J. 1971; Comparison of the tanned red cell hemagglutination inhibition immuno-assay and radial immunodiffusion for the quantitation of fibrinogen-related antigen in urine concentrates. Scandinavian Journal of Haematology Suppl. 13: 225.
• 40 Molla A, Donati M. B, and Vermylen J. 1974; The antigenic determinant of fibrin(ogen) measured with agglutination inhibition immunoassays. Journal of Clinical Pathology 27: 473.
• 41 Niléhn J.E. 1967; Separation and estimation of split “products” of fibrinogen and fibrin in human serum. Thrombosis et Diathesis Haemorrhagica 18: 487.
• 42 Nossel H. L, Yudelman L, Confield R. E, Butler Jr. V. P, Spanondis K, Wilner G. D, and Quereshi G. D. 1974; Measurement of fibrinopeptide Ain human blood. Journal of Clinical Investigation 54: 43.
• 43 Nussenzweig V, Seligmann M, and Grabar P. 1961; Les produits de degradation du fibrinogène humain par la plasmine. IL Etude immunologique: mise en évidence d’anticorps antifibrinogène natif possédant des spécificités différentes. Annales de l’Institut Pasteur (Paris) 100: 490.
• 44 Pitcher P. M. 1972. The use of a rapid latex screening test for the detection of fibrinogen degradation products (FDP) in urine. In: Abstracts of the 3rd. Congress of the International Society on Thrombosis and Haemostasis. Washington: 22-26 August 1972 338.
• 45 Plow E. F, and Edgington T. S. 1973; a Discriminating neoantigenic differences between fibrinogen and fibrin derivatives. Proceedings of the National Academy of Sciences U.S.A 70: 1169.
• 46 Plow E. F, and Edgington T. S. 1973; b Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo. Journal of Clinical Investigation 52: 273.
• 47 Plow E. F, Hougie C, and Edgington T. S. 1973. Immunochemical and molecular investigations of fibrinogen cleavage fragments. In: Poller L. (ed.) Recent Advances in Thrombosis. Churchill Livingstone; Edinburgh: 203.
• 48 Purdie D. W, Howie P. W, Edgar W, Forbes C. D, and Prentice C. R. M. 1975; Baised amniotic fluid FDP in fetal neural tube anomalies. Lancet I: 1013.
• 49 Ratky S. M, Martin M. J, Gordon Y. B, Baker L. R. I, Leslie J, and Chard T. 1975; A comparison between radioimmunoassay and other immunological techniques for the measurement of fibrinogen/fibrin degradation products in serum. British Journal of Haematology 30: 145.
• 50 Scheraga H. A, and Laskowski Jr. M. 1957; The fibrinogen-fibrin conversion. Advances in Protein Chemistry 12: 1.
• 51 Semeraro N, Donati M. B, and Vermylen J. 1973; Rapid latex-screening test for urine FDP. Lancet 1: 1057.
• 52 Soria J, Soria C, Fabiani P, and Samama M. 1973; Determination of fibrinogen degradation products using anti-fibrinogen serum and anti-fragment E serum. Thrombosis Research 3: 339.
• 53 Straub P. W. 1975; A case against heparin therapy of intravascular coagulation. Thrombosis et Diathesis Haemorrhagica 33: 107.
• 54 Svanberg L, Åstedt B, and Ekelund L. 1973; Fibrin/fibrinogen degradation products in amniotic fluid. Thrombosis Research 3: 413.
• 55 Svanberg L, Hedner U, and Åstedt B. 1974; Value of determination of FDP during pregnancy by immunochemical and latex agglutination inhibition methods. Acta Obstetrícia et Gynecologica Scandinavica 53: 81.
• 56 Thomas D. P, Niewiarowski S, Myers A. B, Bloch K. J, and Colman B. W. 1970; A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. New England Journal of Medicine 283: 663.
• 57 Thuot C, and Larrieu M. J. 1971; Fibrinogen degradation products : a critical study of two assay methods. Revue Européenne d’Etudes Cliniques et Biologiques 16: 27.
• 58 Tovi D, Nilsson I. M, and Thulin C. A. 1972; a Fibrinolytic activity of the cerebrospinal fluid after subarachnoid haemorrhage. Acta Neurologica Scandinavica 49: 1.
• 59 Tovi E, Nilsson I. M, and Thulin C. A. 1972; b Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurologica Scandinavica 48: 393.
• 60 Vermylen J, and Donati M. B. 1971. The detection of fibrin(ogen) degradation products. In: Losito R, and Longpré B. (eds.) Current Concepts of Coagulation and Hemostasis. Schattauer Verlag; Stuttgart: 187.
• 61 Verstraete M, Vermylen J, and Donati M. B. (eds.) 1971 Fibrinogen Degradation Products. Scandinavian Journal of Haematology. Suppl. 13..